Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

Rabe, Bjorn, Chalaris, Athena, May, Ulrike, Waetzig, Georg H., Seegert, Dirk, Williams, Anwen Sian ORCID: https://orcid.org/0000-0001-6118-020X, Jones, Simon Arnett ORCID: https://orcid.org/0000-0001-7297-9711, Rose-John, Stefan and Scheller, Jurgen 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111 (3) , pp. 1021-1028. 10.1182/blood-2007-07-102137

Full text not available from this repository.

Abstract

The immunoregulatory cytokine Interleukin-6 (IL6) acts in a pro- and anti-inflammatory fashion. Synthesized by myeloid cells, fibroblasts and endothelial cells, IL6 on target cells, binds to the IL6 receptor (IL6R) and signals via complex formation with the ubiquitously expressed gp130 receptor. Paradoxically, most cells, which respond to IL6 during inflammatory states do not express the IL6R and are themselves not directly responsive to the cytokine. A naturally occurring soluble form of the IL6R renders all cells responsive to IL6. This alternative signaling process is called IL6-trans-signaling. Here we developed a transgenic strategy based on the overexpression of the soluble form of gp130, which specifically blocks all IL6 responses mediated by the soluble IL6R but does not affect IL6 responses via the membrane bound IL6R. In these mice, inflammatory processes are blocked as in IL6-/- mice strongly arguing for a major role of the soluble IL6R during inflammation in vivo.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	20 Oct 2022 08:19
URI:	https://orca.cardiff.ac.uk/id/eprint/27986

Citation Data

Cited 205 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item